Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trialSara Lonardi, Alberto Sobrero, Gerardo Rosati et al.|Annals of Oncology|2016Cited by 56
Metronomic Oral Vinorelbine in Advanced Breast Cancer and Non-Small-Cell Lung Cancer: Current Status and Future DevelopmentMarina Elena Cazzaniga, Guido Bocci, Raffaele Addeo et al.|Future Oncology|2015Cited by 54
Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Shaan Dudani, Daniel Yick Chin Heng, Guillermo de Velasco et al.|Journal of Clinical Oncology|2020Cited by 31
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patientsStefano Cascinu, Rossana Berardi, Gerardo Rosati et al.|European Journal of Cancer|2017Cited by 30
Gram-negative septicemia in patients with hematologic malignanciesGiuseppe Todeschini, Gianluigi Cetto, Fabrizio Vinante et al.|European Journal of Cancer and Clinical Oncology|1984Cited by 24